Search Results - "Wakamoto, Azusa"

An Liquid Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum by Mukai, Yuji, Wakamoto, Azusa, Hatsuyama, Tae, Yoshida, Tatsunari, Sato, Hideki, Fujita, Akihisa, Inotsume, Nobuo, Toda, Takaki

“…Routine therapeutic drug monitoring is a promising approach for the rational use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and…”
Get full text

Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer by Umehara, Kengo, Yama, Kaori, Goto, Keisuke, Wakamoto, Azusa, Hatsuyama, Tae, Honjo, Osamu, Saikai, Toyohiro, Fujita, Akihisa, Sato, Hideki

“…Introduction: Corticosteroids are used to treat immune-related adverse events (irAEs) associated with nivolumab. However, patients with non-small-cell lung…”
Get full text

Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study by Umehara, Kengo, Yama, Kaori, Koike, Nozomi, Takayama, Shintarou, Wakamoto, Azusa, Hatuyama, Tae, Kobayashi, Michiya, Sato, Hideki

“…BackgroundPemetrexed (PEM) is administered over a long term to patients with non-squamous cell lung cancer as a maintenance therapy after platinum combination…”
Get full text

Study on the Antiemetic Effects of Aprepitant in Patients with Lung Cancer Receiving Chemotherapy with Carboplatin by Hatsuyama, Tae, Umehara, Kengo, Wakamoto, Azusa, Sato, Hideki

“…Guidelines for antiemetic therapy, such as the American Society of Clinical Oncology (ASCO) guidelines, recommend that aprepitant, an NK1 receptor antagonist,…”
Get more information

Comparative Study of the Antiemetic Palonosetron for Lung Cancer Patients Treated with a Divided Dose of Cisplatin by Umehara, Kengo, Wakamoto, Azusa, Hatsuyama, Tae, Sato, Hideki, Kobayashi, Michiya, Fujita, Akihisa, Sekine, Kyuichiro

“…Palonosetron(Palo)is a second-generation 5-hydroxytryptamine 3 receptor antagonist(5-HT3RA)effective in suppressing chemotherapy-induced nausea and vomiting in…”
Get more information

Comparative study of an antiemetic NK1 receptor-antagonist in lung cancer patients treated with divided doses for Cisplatin by Sato, Hideki, Wada, Keiko, Umehara, Kengo, Otsu, Keisuke, Wakamoto, Azusa, Hatsuyama, Tae, Fujita, Akihisa, Sekine, Kyuichiro

“…Aprepitant is a NK1 receptor-antagonist with a novel mechanism of action for chemotherapy-induced nausea and vomiting (CINV), and is recommended as a…”
Get more information

The Relationship Between Efficacy and Safety of Osimertinib Blood Concentration in Patients With EGFR Mutation-positive Lung Cancer: A Prospective Observational Study by HASHINO, YASUHISA, HATSUYAMA, TAE, IWAYAMA, KUNINORI, HOSHI, TAKANOBU, WAKAMOTO, AZUSA, OHTAKI, KOICHI, TODA, TAKAKI, SATO, HIDEKI

“…BACKGROUND/AIMOsimertinib blood levels and their impact on treatment continuation in patients with EGFR mutation-positive lung cancer is not known. This study…”
Get full text

Association of Nutritional Indices With Adverse Effects and Time-to-Treatment-Failure in Triple Therapy for Lung Cancer by Hashino, Yasuhisa, Matushita, Takumu, Hatsuyama, Tae, Wakamoto, Azusa, Goto, Keisuke, Hoshi, Takanobu, Iwayama, Kuninori, Ohtaki, Koichi, Toda, Takaki, Sato, Hideki

“…Recent lung cancer treatments include an immune checkpoint inhibitor (ICI) pembrolizumab, platinum-based agents, plus an additional cytotoxic anticancer agent…”
Get full text

Association of Geriatric Nutritional Risk Index With Immune Checkpoint Inhibitor Treatment Duration and Adverse Events in Lung Cancer by Shimizu, Atsuya, Fukasawa, Miyu, Mitani, Koharu, Goto, Keisuke, Wakamoto, Azusa, Hatsuyama, Tae, Hoshi, Takanobu, Hasegawa, Isao, Sato, Hideki

“…Compared to conventional cytotoxic anticancer agent-based therapy, treatment with immune checkpoint inhibitors (ICI) significantly prolongs overall survival…”
Get full text

An LC-MS/MS method for the simultaneous determination of afatinib, alectinib, ceritinib, crizotinib, dacomitinib, erlotinib, gefitinib, and osimertinib in human serum by Mukai, Yuji, Wakamoto, Azusa, Hatsuyama, Tae, Yoshida, Tatsunari, Sato, Hideki, Fujita, Akihisa, Inotsume, Nobuo, Toda, Takaki

Get full text

P3-061Comparative study on safety after primary and secondary treatment in EGFR positive NSCLC administered Osimertinib by Umehara, Kengo, Gto, Keisuke, Okayama, Yuki, Noomote, Shiori, Toda, Takayuki, Okazaki, Yasuka, Wakamoto, Azusa, Hatsuyama, Tae, Honjo, Osamu, Sato, Hideki

“…Abstract Background Since osimertinib significantly prolonged progression free survival compared with conventional EGFR-TKI and was well-tolerated, it was…”
Get full text

Comparative study on safety after primary and secondary treatment in EGFR positive NSCLC administered Osimertinib by Umehara, Kengo, Gto, Keisuke, Okayama, Yuki, Noomote, Shiori, Toda, Takayuki, Okazaki, Yasuka, Wakamoto, Azusa, Hatsuyama, Tae, Honjo, Osamu, Sato, Hideki

Get full text